Conference
Effect Of An Anti-M1 Prime Monoclonal Antibody, MEMP1972A, In A Phase II Proof-Of-Activity Allergen Challenge Study In Patients With Mild Asthma
Authors
Gauvreau G; Boulet L-P; Cockcroft DW; Davis B; Fitzgerald MJ; Leigh R; Dahlen B; Mayers I; Scheerens H; Maciuca R
Pagination
pp. a6793-a6793
Publisher
American Thoracic Society
Publication Date
May 2012
DOI
10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6793
Name of conference
B37. NEW INSIGHTS INTO ASTHMA AND COPD TREATMENT